PDS Biotechnology: Strategic Shift to Triplet Therapy Promises Enhanced Clinical Success

Analyst Mayank Mamtani of B.Riley Financial reiterated a Buy rating on PDS Biotechnology (PDSB – Research Report), with a price target of $11.00.

Mayank Mamtani has given his Buy rating due to a combination of factors related to PDS Biotechnology’s strategic shift and promising clinical data. The reorientation from a doublet therapy approach to a late-stage triplet therapy, incorporating PDS01ADC, an IL-12 targeting ADC, significantly enhances the probability of clinical success. This decision is supported by data demonstrating additive efficacy in survival and objective response rates. Despite a potential delay in the registration-enabling program, this pivot is perceived as a positive move, reflecting a data-driven strategy that has shown impressive results in clinical studies, including durable survival rates and confirmed tolerability in a substantial patient cohort.

The advancement of the IL-12 ADC triplet over the doublet regimen is underscored by its biological and clinical rationale, showing a marked improvement in anti-tumor responses. PDS Biotechnology’s innovative approach targets the tumor core, delivering cytotoxic IL-12 directly to the site of action and fostering a pro-inflammatory environment conducive to a robust and sustained anti-tumor response. The stability of the IL-12 ADC, with its non-cleavable linker, minimizes systemic exposure and related adverse effects. These factors, combined with a safety database of over 300 patients, have led to the anticipation of gaining further market conviction in the triplet development strategy, justifying the adjusted price target despite a potential delay in market entry.

In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $21.00 price target.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

PDS Biotechnology (PDSB) Company Description:

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded on March 15, 2019 and is headquartered in Berkeley Heights, NJ.